BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//GrantMe Tennessee//grantme.click//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a)
  for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD)
  and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:2d4c6776-42ec-4d79-83d1-e44dad06a5dd-close@grantme.click
DTSTAMP:20261007T012948Z
DTSTART;VALUE=DATE:20261119
DTEND;VALUE=DATE:20261120
SUMMARY:Deadline: Seamless Early-Stage Clinical Drug Development (Phase 1 t
 o 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease
  (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
URL:https://grantme.click/grants/2d4c6776-42ec-4d79-83d1-e44dad06a5dd
DESCRIPTION:Confirm the deadline and time zone on the funder's official pag
 e.
TRANSP:TRANSPARENT
BEGIN:VALARM
ACTION:DISPLAY
TRIGGER:-P30D
DESCRIPTION:30 days left: Deadline: Seamless Early-Stage Clinical Drug Deve
 lopment (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of A
 lzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical 
 Trial Required)
END:VALARM
BEGIN:VALARM
ACTION:DISPLAY
TRIGGER:-P7D
DESCRIPTION:7 days left: Deadline: Seamless Early-Stage Clinical Drug Devel
 opment (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Al
 zheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical T
 rial Required)
END:VALARM
END:VEVENT
END:VCALENDAR